A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA)

Annals of Clinical Microbiology and Antimicrobials

Volumn 6, Issue , 2007, Pages

  Voss, Andreas ^a,b   Mouton, Johan W ^b   van Elzakker, Erika P ^c   Hendrix, Ron G ^d   Goessens, Wil ^e   Kluytmans, Jan A ^f   Krabbe, Paul F ^a   de Neeling, Han J ^g   Sloos, Jacobus H ^h   Oztoprak, Nefise ⁱ   Howe, Robin A ^j   Walsh, Timothy R ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c Department of Medical Microbiology   (Netherlands)

^d Laboratory of Medical Microbiology Twente Achterhoek   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f AMPHIA HOSPITAL   (Netherlands)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^h Location Alkmaar   (Netherlands)

ⁱ ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^j SOUTHMEAD HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; GENE DUPLICATION; GENETIC VARIABILITY; GLYCOPEPTIDE INTERMEDIATELY SUSCEPTIBLE STAPHYLOCOCCCUS AUREUS; HETEROGENOUS GLYCOPEPTIDE INTERMEDIATELY SUSCEPTIBLE STAPHYLOCOCCCUS AUREUS; METHODOLOGY; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; REPRODUCIBILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; NETHERLANDS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; INCIDENCE; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 35448976939     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-6-9     Document Type: Article

References (24)

1. Arakawa Y Ike Y Nagasawa M Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone? Lancet 2004 363 1401 10.1016/ S0140-6736(04)16068-6 15110512
2. Fridkin SK Hageman J McDougal LK Mohammed J Jarvis WR Perl TM Tenover TC Epidemiological and microbiological characterization of infections by Staphylococcus aureus with reduced susceptibility to vancomycin, United States 1997-2001 Clin Infect Dis 2003, 36:429-39 10.1086/346207 12567300
3. Gemmell CG Glycopeptide resistance in Staphylococcus aureus: Is it a real threat? J Infect Chemother 2004, 10:69-75 10.1007/s10156-004-0307-5 15160298
4. Goldstein FW Kitzis MD Vancomycin-resistant Staphylococcus aureus: No apocalypse now Clin Microbial Infect 2003, 9:761-765 10.1046/ j.1469-0691.2003.00734.x
5. Hiramatsu K Hanaki K Ino T Yabuta K Oguri T Tenover FC Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 1997, 40:135-6 10.1093/ jac/40.1.135 9249217
6. Howe RA Monk A Wootton M Walsh TR Enright MC Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages Emerg Infect Dis 2004, 10:855-857 15200819
7. Howe RA Walsh TR hGISA: Seek and you shall find Lancet 2004, 364:500-501 10.1016/S0140-6736(04)16803-7 15302189
8. Walsh TR Howe RA The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus Ann Review Microbiol 2002, 56:657-75 10.1146/ annurev.micro.56.012302.160806
9. Smith TL Pearson ML Wilcox KR Cosme Cruz PH Lancaster MV Robinson-Dunn B Tenover FC Zervos MJ Band JD White E Jarvis WR Emergence of vancomycin resistance in Staphylococcus aureus N Engl J Med 1999, 340:493-501 10.1056/NEJM199902183400701 10021469
10. Chang S Sievert DM Hageman JC Bolton HL Tenover FC Downes FP Shah S Rudrik JT Pupp GR Brown WJ Cardo S Fridkin SK Infection with vancomycin-resistant Staphylococcus aureus containing the van resistance gene N Eng J Med 2003, 348:1342-7 10.1056/NEJMoa025025
11. Tenover FC Weigel LM Applebaum PC McDougal LK Chaitram J McAllister S Clark N Killgore G O'Hara CM Je L Patel JB Bozdogan B Vancomycin-resistant Staphylococcus aureus isolated from a patient in Pennsylvania Antimicrob Agents Chemother 2004, 48:275-80 310200 14693550 10.1128/AAC.48.1.275-280.2004
12. MacGowan AP Wise R Establishing MIC breakpoints and the interpretation on in-vitro susceptibility tests BSAC News letter 2004: P48-71
13. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Approved Standard M7-A6 NCCLS, Villanova, PA. Sixth 2003
14. Cui L Ma X Sato K Okuma K Tenover FC Mamizuka EM Gemmell CG Kim MN Ploy M-C El-Solh N Ferraz V Hiramatsu K Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus J Clin Microbiol 2003, 41:5-14 149586 12517819 10.1128/JCM.41.1.5-14.2003
15. Hanaki H Labischinksi H Inaba Y Kondo N Murakami H Hiramatsu K Increase in glutamine-non-amidated muropeptides and peptdioglycan of vancomycin-resistant Staphylococcus aureus strain, Mu50 J Antimicrob Chemother 1998, 42:315-20 10.1093/jac/42.3.315 9786471
16. Tenover FC Lancaster MV Hill B Steward C Socker S Hancock G O'Hara C Clark N Hiramatsu K Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides J Clin Microbiol 1998, 36:1020-1027 104681 9542929
17. Charles PGB Ward PB Johnson DPR Howden BP Grayson ML Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate Staphylococcus aureus Clin Infect Dis 2004, 38:448-51 10.1086/381093 14727222
18. Howe RA Wootton M Walsh TR Bennett PM MacGowan AP Heterogeneous resistance to vancomycin in Staphylococcus aureus J Antimicrob Chemother 2000, 45:130 10.1093/jac/45.1.130 10629026
19. Hubert SK Mohammed JM Fridkin SK Gaynes RP McGowan JE Tenover FC Glycopeptide-Intermediate Staphylococcus aureus: Evaluation of a novel screening method and results of a survey of selected U.S. hospitals J Clin Microbiol 1999, 37:3590-3593 85700 10523558
20. Walsh TR Bolmström A Qwarnström A Ho P Wootton M Howe RA MacGowan AP Diekema D Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides J Clin Microbiol 2001, 39:2439-44 88167 11427551 10.1128/JCM.39.7.2439-2444.2001
21. Wootton M MacGowan AP Walsh TR Howe RA A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides Journal of Clin Mic 2007, 45:329-332 10.1128/JCM.01508-06
22. Wootton M Howe RA Hillman R Walsh TR Bennett PM MacGowan AP A modified population analysis profile method to detect Staphylococcus aureus with decreased susceptibilities to vancomycin in a UK hospital J Antimicrob Chemother 2001, 47:399-404 10.1093/jac/47.4.399 11266410
23. El Sohl N Davi M Morvan A Damon HA Marty N GISA Group RAISIN subgroup Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides J Antimicrob Chemother 2003, 52:691-4 10.1093/jac/dkg400 12951351
24. SPSS http://spss.com